Latest Articlesddd

Another Approval for Celgene and the First for Acceleron

November 12, 2019 0

FDA Approval for Celgene and Acceleron Drug REBLOZYL® The U.S. Food and Drug Administration (FDA) has …

What A Week For Biotechnology

November 11, 2019 0

The Week in Review #47 What A Week For Biotechnology Synopsis In this “Week in Review” …

Exelixis and Daiichi Sankyo: Preventing and Treating Diabetic Nephropathy

November 8, 2019 0

Exelixis and Daiichi Sankyo Partner to Prevent and Treat Diabetic Nephropathy Exelixis (EXEL) and Daiichi Sankyo …

The Bad News That Might Save the Life of Halozyme Therapeutics

November 6, 2019 0

Halozyme Therapeutics is Focusing on ENHANZE® Technology Halozyme Therapeutics (HALO) decides to focus on its ENHANZE® …

Karyopharm Therapeutics: Is a Star Born?

November 6, 2019 0

Karyopharm Therapeutics Third Quarter Financial Results Generated Revenues For the first time since its establishment Karyopharm …

The FDA Approves Compugen’s IND for Its Oncology Product COM902

November 4, 2019 0

Compugen FDA Approval for COM902 Compugen Announces FDA Clearance of IND Application for COM902 Phase 1 …

The Quarterly Financial Results

November 4, 2019 0

The Week in Review #46 The Quarterly Financial Results The quarterly financial results that analysts and …

IVERIC bio Stock Doubled and Continues to Outperform

November 1, 2019 0

IVERIC bio Stock Outperforms IVERIC bio (ISEE) has good news its stock is responding to. A …

When Negative Reactions to Biotechnology News Mislead. The Case of Regenxbio.

October 31, 2019 0

Regenxbio Misleading Selloff A selloff of Regenxbio (RGNX) stock, following the FDA’s partial hold on the …

What Was Seen and What Was Ignored

October 29, 2019 0

The Week in Review #44 Quarterly Financial Results What Was Seen and What Was Ignored History …

Can the Combination of Inarigivir from Spring Bank Pharmaceuticals and Vemlidy from Gilead Sciences Succeed in Treating Chronic Hepatitis B Viral Infection

October 24, 2019 0

Spring Bank Pharmaceuticals, Gilead Sciences and HBV If Spring Bank Pharmaceuticals’ (SBPH) product inarigivir in combination …

This Past Week

October 22, 2019 0

The Week in Review #43 This Past Week After hearing hints about the trade war between …

Why Seattle Genetics Gained $13.29; Currently Trading at $100.69; Meeting the Prohost 2019 Target

October 21, 2019 0

Seattle Genetics Announced Positive Results for HER2CLIMB Trial Seattle Genetics (SGEN) announced positive topline results from …

Bayer Decision to Advance IONIS-FXI-LRx Following Positive Results. See Also: Why Hepion Pharmaceuticals Stock Almost Doubled Today

October 17, 2019 0

Bayer Decision to Advance IONIS-FXI-LRx for Clotting Disorders On October 9, 2019 Ionis Pharmaceuticals (IONS) announced …

Hepion Pharmaceuticals’ Product CRV431 Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models.

October 17, 2019 0

Hepion Pharmaceuticals CRV431 Decreased Liver Fibrosis and Tumor Burden in Experimental Models EDISON, NJ / ACCESSWIRE …

Reata Pharmaceuticals’ Product Omaveloxolone Met the Trial Primary Endpoints in Treating Friedreich’s Ataxia

October 16, 2019 0

Reata Pharmaceuticals Omaveloxolone for Friedreich’s Ataxia On October 14, 2019 Reata Pharmaceuticals (RETA) announced the Part 2 …

RegenxBio is Rebounding. See Also: A Scientifically Valuable Agreement Between CRISPR Therapeutics and KSQ Therapeutics

October 15, 2019 0

RegenxBio Rebounding RegenxBio (RGNX) has the viral vectors which could safely deliver genes into the cells. …

Results From Phase I/IIa Trial of RegenxBio Gene Therapy Product RGX-314

October 14, 2019 0

RegenxBio Interim Data from Phase I/IIa Trial of RGX-314 for Wet AMD RegenxBio (RGNX) announced interim …

Novartis: Plenty of Good News. See Also: Topics We Will Address in an Upcoming Week in Review

October 11, 2019 0

Stock Market Volatility  Stocks can move up and down for various reasons but not all of …

More News for Nektar Therapeutics

October 8, 2019 0

Nektar Therapeutics Announces Two Studies of NKTR-358 Nektar Therapeutics (NKTR) announced the initiation of two Phase 1b …